Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing.

Pfizer is facing another setback with its weight-loss pill, danuglipron. The pharmaceutical giant stopped development of the drug after liver issues affected one patient.

Pfizer to discontinue its GLP-1 pill for obesity due to liver toxicity CEO previously said the company is ‘determined’ to be in obesity Mark Lennihan/AP By Matthew Herper April 14, 2025 ...

Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug development, including its obesity drug danuglipron.

Pfizer teams up with Alloy for antibody discovery Feb. 11, 2025 9:35 AM ET Pfizer Inc. (PFE) Stock By: Val Brickates Kennedy, SA News Editor 1 Comment Play (<1min) georgeclerk ...